COURT-RULING ·Filed Sep 14, 2026

ABT

ABBOTT LABORATORIES
NEUTRAL
Impact 1/10
Horizonimmediate Processed16d 13h ago CourtView Ruling on CourtListener
Court ruling (district)
Actionable Insight • Neutral

This is a non-event for ABT. Monitor the October 6, 2026 ESI protocol deadline and any subsequent discovery disputes, but this filing provides no actionable trading signal.

DirectionNeutral
Confidencehigh
Horizonimmediate
Latest settled — T+5d
ABT ▼ -0.11% at T+5d
NEUTRAL call ✗ call lost -0.11% · α vs SPY -1.77% · entry $103.09 → $102.98
Next anchor: T+20d in 7d
Latest observation: T+11 +3.41% FF3 residual α
Entry anchored
Sep 11, 06:39 PM ET
via 1-min bar
T+1d
-1.03%
call -1.03% · α -0.57%
$102.03
settled 18d ago
T+5d
-0.11%
call -0.11% · α -1.77%
$102.98
settled 14d ago
T+20d
—
call — · α —
—
in 7d
T+60d
—
call — · α —
—
in 2mo

Price Chart

Loading chart...

Executive Summary

This is a routine procedural order in a consumer class action against Abbott Diabetes Care and Abbott Laboratories regarding FreeStyle CGM products. The parties jointly stipulated to extend the deadline to submit a proposed ESI protocol from September 14, 2026 to October 6, 2026. The order contains no substantive rulings on liability, damages, or injunctive relief — it is a scheduling extension, the fourth such request, with no impact on any other case deadlines. For a $178B market cap company, this is immaterial housekeeping.

Key Facts

  • Court granted a joint stipulation to extend the deadline for submitting a proposed ESI protocol from September 14, 2026 to October 6, 2026.
  • This is the fourth stipulated extension of this deadline in the FreeStyle CGM consumer litigation.
  • The order does not alter any other case deadlines or events.
  • No substantive ruling on liability, damages, or injunctive relief was made.

Financial Impact

No financial impact — purely procedural scheduling order with no monetary exposure stated.

Risk Factors

  • Ongoing consumer class action creates eventual settlement or adverse judgment tail risk, but this procedural step does not change that risk profile.

Market Snapshot

Price
$102.00
Volume
200
Exchange
NYSE
Sector
Pharmaceutical Preparations
Analyst Consensus
76% bullish (33 analysts)

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 1 court opinion from CourtListener.

DocumentAccession Number
COURT-RULING Data (Synthetic)court-82d0c37cee-ABT
22 reports for ABT
Performance horizon
80% Hit rate 4 of 5 directional calls best @ T+20▲ +17.16%Jul 1, 2026
Filters
Rows
Reports for ABT — sortable, filterable
TypeNow
Oct 2, 2026
today
ANALYST-UPGRADE
BULLISH ★ 4/10
$98.00 awaiting T+5awaiting T+5—$96.30 (−1.73%)
Sep 14, 2026
18d ago
Court Ruling
NEUTRAL ★ 1/10
$103.09 $102.98▼ −0.11%▼ −1.77%$96.30 (−6.59%)
Aug 11, 2026
7w ago
Court Ruling
NEUTRAL ★ 2/10
$109.72 $112.68▲ +2.70%▲ +3.10%$96.30 (−12.23%)
Aug 11, 2026
7w ago
Court Ruling
NEUTRAL ★ 1/10
$109.72 $112.68▲ +2.70%▲ +3.10%$96.30 (−12.23%)
Jul 31, 2026
9w ago
Institutional Cluster
MIXED ★ 4/10
$105.70 $107.81▲ +2.00%▼ −1.51%$96.30 (−8.89%)
Jul 31, 2026
9w ago
Court Ruling
NEUTRAL ★ 2/10
$105.70 $107.81▲ +2.00%▼ −1.51%$96.30 (−8.89%)
Jul 24, 2026
10w ago
Court Ruling
BULLISH ★ 5/10
$103.06 $105.61▲ +2.47%▲ +2.10%$96.30 (−6.56%)
Jul 16, 2026
11w ago
8-K
BULLISH ★ 6/10
$98.83 $100.75▲ +1.94%▲ +3.61%$96.30 (−2.56%)
Jul 14, 2026
11w ago
Court Ruling
NEUTRAL ★ 3/10
$88.96 $101.66▲ +14.28%▲ +15.57%$96.30 (+8.25%)
Jul 7, 2026
12w ago
Court Ruling
NEUTRAL ★ 1/10
$95.84 $88.96▼ −7.18%▼ −7.73%$96.30 (+0.48%)
Showing 10 of 22

US Market Status

Market Open — Closes in 6h 27m

Subscribe to SecBot

Get Real-Time Court Ruling Intelligence

Market-moving court rulings analyzed within minutes. Patent verdicts, antitrust decisions, class certifications, and more — parsed and scored by AI.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access